Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting: preliminary analysis in a Chinese cohort

Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting: preliminary analysis in a Chinese cohort

Saved in:
Bibliographic Details
Published in:Translational lung cancer research Vol. 11; no. 12; pp. 2495 - 2506
Main Authors: Zou, Zihua, Gu, Yangchun, Liang, Li, Hao, Xuezhi, Fan, Chengjuan, Xin, Tao, Zhao, Songchen, Liu, Ziling, Guo, Ye, Ma, Kewei, Li, Haojing, Zhang, Cuiying, Shan, Li, Zhang, Yan, Dong, Guilan, Peng, Yumei, Shen, Fangfang, Song, Xia, Christopoulos, Petros, Wekken, Anthonie J. van der, Okuda, Katsuhiro, Ekman, Simon, Xing, Puyuan, Li, Junling
Format: Journal Article
Language:English
Published: AME Publishing Company 01-12-2022
Subjects:
Original
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Bibliography:Contributions: (I) Conception and design: Z Zou, P Xing, J Li; (II) Administrative support: P Xing, J Li; (III) Provision of study materials or patients: L Liang, X Hao, T Xin, Z Liu, K Ma, C Zhang, L Shan, G Dong, X Song, P Xing, J Li; (IV) Collection and assembly of data: Z Zou, Y Gu, C Fan, S Zhao, Y Guo, H Li, Y Zhang, Y Peng, F Shen; (V) Data analysis and interpretation: Z Zou, Y Gu; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.
These authors contributed equally to this work and should be considered as co-first authors.
ISSN:2218-6751
2226-4477
DOI:10.21037/tlcr-22-803